Orchestra BioMed to Present Virtue Balloon at TCT 2026
The clinical design and mechanism of the Virtue Trial will be unveiled during the TCT symposium on November 1.
Updated on Oct. 29, 2026 in Heart Disease
Live Poll
Do you trust that newer medical technologies consistently provide better long-term health outcomes for patients?
Orchestra BioMed is scheduled to present its Virtue Sirolimus AngioInfusion Balloon at the TCT 2026 symposium in San Diego. The presentation on November 1, 2026, will detail the trial design and clinical mechanism of the device.
Why it matters
The Virtue Sirolimus AngioInfusion Balloon is designed to inhibit proliferation and modulate inflammation in the vessel wall. Data from this trial aims to clarify the device's efficacy compared to existing treatment options in the cardiovascular space.
The upcoming trial intends to enroll 740 patients to evaluate the device. This study follows the earlier SABRE research which observed a 14.3% target lesion failure rate among 50 participants over three years.
The players
Orchestra BioMed
This company is a biomedical firm headquartered in New Hope, Pennsylvania, focused on developing interventional cardiovascular therapies.
Allen Jeremias
He is the lead presenter scheduled to explain the design and clinical mechanism of the Virtue Trial during the symposium.
Medtronic
This global medical device corporation maintains a strategic collaboration with Orchestra BioMed regarding AVIM Therapy.
The details
The technology works by infusing a liquid volume of SirolimusEFR directly into the vessel wall through a microporous balloon. Researchers will compare this method against the AGENT paclitaxel-coated balloon during the multicenter study.
Timeline
The TCT 2026 symposium begins on October 31, 2026.
The Virtue Trial presentation occurs on November 1, 2026.
The TCT 2026 symposium concludes on November 3, 2026.
The Big Picture
The TCT 2026 symposium serves as a primary venue for cardiovascular research updates, where clinical trial milestones are benchmarked against existing standards of care. The presentation of the Virtue Trial marks the device's entry into the broader evidence-gathering phase highlighted by this academic forum.
This research could eventually expand available treatment options for patients requiring vessel wall therapy. Clinicians and patients will gain more insight into device performance as the study progresses toward its 740-patient enrollment goal.
The takeaway
The development of non-coated drug delivery systems reflects a shift toward specialized therapies in interventional cardiology. Ongoing trials remain the essential mechanism for verifying if these new devices provide long-term safety and success for patients.
Further reading
Learn more about the latest innovations in Heart Disease.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that newer medical technologies consistently provide better long-term health outcomes for patients?
